Moderna, Inc is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based on messenger RNA.
Company profile
Ticker
MRNA, 0A45
Exchange
Website
CEO
Stephane Bancel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Exelixis • Acorda Therapeutics ...
Former names
Moderna Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Brizo Ltd. • Moderna Australia Pty Ltd • Moderna Austria GmbH • Moderna Belgium SRL • Moderna Biopharma Canada Corporation • Moderna Biotech Distributor UK Ltd. • Moderna Biotech Ireland Limited • Moderna Biotech Kenya Manufacturing Ltd. • Moderna Biotech Manufacturing UK Ltd. • Moderna Biotech Securities, Inc. ...
IRS number
813467528
MRNA stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
5 May 23
S-3ASR
Automatic shelf registration
5 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
4 May 23
DEFA14A
Additional proxy soliciting materials
14 Apr 23
PX14A6G
Letter to shareholders
13 Apr 23
DEFA14A
Additional proxy soliciting materials
15 Mar 23
DEF 14A
Definitive proxy
15 Mar 23
ARS
2022 FY
Annual report to shareholders
27 Feb 23
10-K
2022 FY
Annual report
24 Feb 23
Transcripts
MRNA
Earnings call transcript
2023 Q1
4 May 23
MRNA
Earnings call transcript
2022 Q4
23 Feb 23
MRNA
Earnings call transcript
2022 Q3
3 Nov 22
MRNA
Earnings call transcript
2022 Q2
3 Aug 22
MRNA
Earnings call transcript
2022 Q1
4 May 22
MRNA
Earnings call transcript
2021 Q4
24 Feb 22
MRNA
Earnings call transcript
2021 Q3
5 Nov 21
MRNA
Earnings call transcript
2021 Q2
5 Aug 21
MRNA
Earnings call transcript
2021 Q1
7 May 21
MRNA
Earnings call transcript
2021 Q1
14 Apr 21
Latest ownership filings
4
NOUBAR AFEYAN
2 Jun 23
144
Notice of proposed sale of securities
2 Jun 23
144
Notice of proposed sale of securities
2 Jun 23
4
Stephane Bancel
2 Jun 23
144
Notice of proposed sale of securities
1 Jun 23
144
Notice of proposed sale of securities
31 May 23
4
Stephen Hoge
31 May 23
144
Notice of proposed sale of securities
31 May 23
144
Notice of proposed sale of securities
30 May 23
4
Stephane Bancel
26 May 23
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 3.46 bn | 3.46 bn | 3.46 bn | 3.46 bn | 3.46 bn | 3.46 bn |
| Cash burn (monthly) | (no burn) | 133.25 mm | 122.00 mm | (no burn) | 408.33 mm | (no burn) |
| Cash used (since last report) | n/a | 286.82 mm | 262.60 mm | n/a | 878.93 mm | n/a |
| Cash remaining | n/a | 3.17 bn | 3.20 bn | n/a | 2.58 bn | n/a |
| Runway (months of cash) | n/a | 23.8 | 26.2 | n/a | 6.3 | n/a |
Institutional ownership, Q1 2023
77.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 971 |
| Opened positions | 113 |
| Closed positions | 175 |
| Increased positions | 312 |
| Reduced positions | 369 |
| 13F shares | Current |
|---|---|
| Total value | 37.63 tn |
| Total shares | 294.81 mm |
| Total puts | 8.73 mm |
| Total calls | 10.12 mm |
| Total put/call ratio | 0.9 |
| Largest owners | Shares | Value |
|---|---|---|
| Baillie Gifford & Co | 46.47 mm | $7.14 tn |
| Vanguard | 27.53 mm | $4.23 tn |
| BLK Blackrock | 25.09 mm | $3.85 tn |
| Ofi Invest Asset Management | 21.43 mm | $139.66 mm |
| Flagship Ventures Fund IV General Partner | 17.58 mm | $0.00 |
| STT State Street | 14.08 mm | $2.16 tn |
| Flagship Pioneering | 12.89 mm | $1.98 tn |
| Bancel Stephane | 9.05 mm | $0.00 |
| Coatue Management | 6.55 mm | $1.01 tn |
| Geode Capital Management | 6.24 mm | $957.06 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Jun 23 | Bancel Stephane | Common Stock | Sell | Dispose S | No | Yes | 128.18 | 29,979 | 3.84 mm | 5,411,946 |
| 1 Jun 23 | Bancel Stephane | Common Stock | Sell | Dispose S | No | Yes | 127.53 | 8,611 | 1.10 mm | 5,441,925 |
| 1 Jun 23 | Bancel Stephane | Common Stock | Sell | Dispose S | No | Yes | 125.96 | 1,410 | 177.60 k | 5,450,536 |
| 1 Jun 23 | Bancel Stephane | Common Stock | Option exercise | Acquire M | No | Yes | 0 | 40,000 | 0.00 | 5,451,946 |
| 1 Jun 23 | Bancel Stephane | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 0 | 40,000 | 0.00 | 267,155 |
| 31 May 23 | Bancel Stephane | Common Stock | Sell | Dispose S | No | Yes | 128.42 | 4,850 | 622.84 k | 5,411,946 |
| 31 May 23 | Bancel Stephane | Common Stock | Sell | Dispose S | No | Yes | 127.84 | 11,036 | 1.41 mm | 5,416,796 |
| 31 May 23 | Bancel Stephane | Common Stock | Sell | Dispose S | No | Yes | 126.71 | 14,636 | 1.85 mm | 5,427,832 |
| 31 May 23 | Bancel Stephane | Common Stock | Sell | Dispose S | No | Yes | 125.38 | 9,478 | 1.19 mm | 5,442,468 |
| 31 May 23 | Bancel Stephane | Common Stock | Option exercise | Acquire M | No | Yes | 0 | 40,000 | 0.00 | 5,451,946 |
News
Looking At Moderna's Recent Unusual Options Activity
30 May 23
Moderna Announces Phase 2 Data On mRNA-4157 (V940) To Be Presented At 2023 ASCO Annual Meeting
30 May 23
10 Health Care Stocks Whale Activity In Today's Session
26 May 23
10 Health Care Stocks With Whale Alerts In Today's Session
25 May 23
GeoVax's Next-Gen Single Dose COVID-19 Vaccine Shows Promising Results
24 May 23
Press releases
Moderna to Present at Upcoming Conferences in June 2023
1 Jun 23
Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
30 May 23
Financial Literacy for All Welcomes American Express, Dow Jones, and Moderna to its Mission of Advancing Financial Literacy
25 May 23
Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
19 May 23
Montai Health Adds Industry Leaders to its Board of Directors
17 May 23